Pharmaceutical combination comprising a selective s1p1 receptor agonist
AssigneeVanda Pharmaceuticals Inc.
InventorsMartine CLOZEL, Luca PIALI
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pharmaceutical combination comprising a first active ingredient which is (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]propylimino)-3-o-tolyl-thiazolidin-4-one or a pharmaceutically acceptable salt thereof and a second active ingredient which is selected from the group consisting of methyl fumarate, dimethyl fumarate, (N,N-diethylcarbamoyl)methyl methyl (2E) but-2-ene-1,4-dioate, and 2-(2,5-dioxopyrrolidin-1-yl)ethyl methyl (2E) but-2-ene-1,4-dioate, or a pharmaceutically acceptable salt thereof.
Claims10
A method of treating a patient suffering from multiple sclerosis, the method comprising:
- administering to the patient about 10 mg of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one or a pharmaceutically acceptable salt thereof and a synergistically effective amount of dimethyl fumarate or a pharmaceutically acceptable salt thereof.
A method of treating a patient suffering from multiple sclerosis, the method comprising:
- administering to the patient about 20 mg of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one or a pharmaceutically acceptable salt thereof and a synergistically effective amount of dimethyl fumarate or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.